Skip to main content

diphenhydramine

Generic: DIPHENHYDRAMINE HYDROCHLORIDE·Brand: ANTITUSSIVE, Acetadryl, Aleve PM, BELDIN, BELIX, BENADRYL, BENADRYL PRESERVATIVE FREE, BENYLIN, Banophen, Banophen Cream, Benadryl, Benadryl Allergy Plus Congestion, Benadryl Itch Stopping, Benadryl-D Allergy and Sinus, Buckley's Bedtime Formula, Calagel, Calagel Reformulated Jun 2019, Compoz, DIBENIL, DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, Dermamycin, Diphedryl, Diphenhist, Doans PM, Dormin, Excedrin PM, Excedrin PM Triple Action, Genahist, HYDRAMINE, Kids-Eeze Allergy, Legatrin PM, Motrin PM, Nytol, Panadol PM, Pediaclear Cough, Percogesic Reformulated Jan 2011, Rest Simply, SILPHEN, Scot-Tussin Allergy, Siladryl, Simply Sleep, Sleep-Eze, Sleepinal, Sominex, Somnapure, Tact, Tekral, The Itch Eraser, Twilite, Tylenol PM, Unisom Sleep, Unisom with Pain Relief, VICKS FORMULA 44, Vanamine, Vetadryl, Wal-Dryl, Wal-Dryl Allergy, Wal-Dryl Childrens, Wal-Dryl PE, Wal-Dryl-D, Wal-Sleep Z, Wal-Som, Wal-Som Maximum Strength, Z-Sleep, ZZZ Sleep, Zzzquil

diphenhydramine: 20 clinical trials tracked.

diphenhydramine evidence translation

What we can confirm

20 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about diphenhydramine, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 6 study sponsors
Clinical Trials (20)showing 10 most recent

Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

NCT04456439·MESO
No longer available
Expanded AccessMesoblast International Sàrl

A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies

NCT07709000·Phase 2
Not yet recruiting

Primary endpoint: Cohort A Part 1: Number of Participants Who Experience Dose-Limiting Toxicity (DLT)

Interventionalsingle60 targetStarted 2026-09Completion 2033-113 sites · IsraelMerck Sharp & Dohme LLC

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT07570173·Phase 2/Phase 3
Recruiting

Primary endpoint: Percentage of Participants with Complete Remission (CR) in Study Part 1 and Part 2

InterventionalRandomizedsingle340 targetStarted 2026-05Completion 2033-1019 sites · Denmark, Greece, Israel, Italy…Merck Sharp & Dohme LLC

A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT06356571·Phase 2·SNY
Recruiting

Primary endpoint: Overall response rate (ORR)

Interventionalopen64 targetStarted 2025-03Completion 2027-0734 sites · United StatesSanofi

Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

NCT05896228·Phase 2
Recruiting

Primary endpoint: Rate of MRD-negativity: Iber-KDd Combination therapy.

Interventionalopen30 targetStarted 2024-02Completion 2031-031 site · United StatesBenjamin T Diamond, MD

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

NCT06043323·Phase 2·FLNA
Recruiting

Primary endpoint: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Interventionalopen20 targetStarted 2024-01Completion 2028-091 site · United StatesM.D. Anderson Cancer Center

Efficacy of Nasal Migraine Cocktail Used In Pediatric Emergency Department: A Clinical Trial

NCT06083571·Phase 2
Terminated

Primary endpoint: Change from baseline in pain on the 10 point Faces Pain Scale-Revised in 2 hours

InterventionalRandomizedquadruple41 targetStarted 2024-01Completion 2025-121 site · United StatesWashington University School of Medicine

A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion

NCT06019728·Phase 4·SNY
Completed

Primary endpoint: Percent Reduction in Shortest Tolerated Infusion Duration From Pre-study Average of Recent 3 Infusions

Interventionalopen8 enrolledStarted 2023-11Completion 2024-105 sites · United StatesSanofi

A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT05704049·Phase 2·SNY
Active, not recruiting

Primary endpoint: Overall response rate (ORR) - Cohorts 1 to 3

InterventionalRandomizedopen118 targetStarted 2023-04Completion 2028-0523 sites · Australia, Brazil, China, Czechia…Sanofi

A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT05405166·Phase 3·SNY
Active, not recruiting

Primary endpoint: Overall Response Rate (ORR)

InterventionalRandomizedopen531 targetStarted 2022-06Completion 2027-0350 sites · Argentina, Australia, Brazil, Canada…Sanofi